|
시장보고서
상품코드
2129053
질염 치료제 시장 : 질환별, 제품별, 유통 채널별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Vaginitis Therapeutics Market, By Disease, By Product, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
질염 치료제 시장 규모는 2025년에 40억 5,130만 달러로 평가되었고, 2026-2033년 CAGR 8.1%로 성장할 전망입니다.
질염 치료제는 질 감염의 치료를 목적으로 항진균제, 항생제, 호르몬제 등의 약물을 투여하는 것입니다. 이러한 약물은 가려움증, 분비물, 통증 등의 증상을 완화하는 데 매우 효과적입니다.
질염의 주요 치료제 유형로는 니트로이미다졸계 약물, 링코사미드계 항생제, 트리아졸계 약물, 그리고 이미다졸계 약물이 포함됩니다. 니트로이미다졸 계열 약물은 항균제로, 기생충, 마이코박테리움, 그리고 혐기성 그람 양성균 및 그람 음성균에 대해 사용됩니다. 세균성 질염, 트리코모나스증, 외음부-질 칸디다증 등 다양한 질환에 대해 경구, 외용, 질 내 투여 등의 투여 경로로 사용됩니다. 최종 사용자로는 병원, 산부인과 센터, 수술센터, 진료소 등이 포함됩니다.
질염 치료제 시장 : 시장 역학
성매개감염(STD) 유병률 증가가 시장 수요를 견인
성병(STD), 특히 트리코모나스증 환자 수가 증가하고 있는 것은 질염 치료제 시장의 주요 촉진요인 중 하나입니다. 이는 증상을 완화하고, 합병증을 예방하며, 감염증에 대처하기 위해 항균제를 사용하여 이러한 질환을 적절히 치료할 필요성이 높아지고 있기 때문입니다. 예를 들어, 2025년 4월,『Cureus』지에 게재되었으며 미국 국립생물공학정보센터(NCBI)를 통해 입수 가능한 5만 명 이상의 환자 결과를 바탕으로 한 연구에 따르면, 성병(STD) 유병률은 16.2%로 기록되었으며, 전 세계적으로 이러한 질환의 유병률이 상승함에 따라 질염 치료제 및 치료법에 대한 수요가 증가할 것으로 예측됩니다. 이처럼 증가하는 질병 부담으로 인해 효과적인 질염 치료제 및 치료법에 대한 수요가 높아질 것으로 예측됩니다.
질염 치료제 시장 : 시장 세분화 분석
세계 질염 치료제 시장은 질환, 제품, 유통 채널 및 지역을 기준으로 세분화되어 있습니다.
질염의 일반적인 아형 중 하나인 세균성 질염은 항상 항균제 치료가 필요한 데다, 다양한 유형의 질염에 대한 인식이 높아지고 감염 재발률이 증가함에 따라, 항균 요법은 질염 치료제 시장에서 큰 비중을 차지하고 있습니다. 예를 들어, 2026년 5월 영국 정부의 보고서에 따르면, 잉글랜드의 항생제 내성 혈류 감염 사례 수는 1만 8,103건에서 2만 484건으로 13.1% 증가했습니다. 또한, 특정 세균성 혈류 감염증의 사례 수는 17만 3,513건에서 18만 3,990건으로 증가하여, 세균 및 그 감염증의 중요성이 높아지고 있으며, 효과적인 항균제에 대한 수요가 증가하고 있음을 보여줍니다. 이러한 추세는 세균성 감염증을 관리하기 위한 효과적인 항균 요법에 대한 수요가 높아지고 있음을 여실히 보여줍니다.
제품 유형별로 보면, 질염 치료제 시장에서는 처방약이 큰 점유율을 차지하고 있습니다. 이는 이러한 약제가 중증, 만성 및 복잡한 질 감염에 대해 전문적이고 의학적으로 관리된 치료법을 제공하기 때문입니다. 예를 들어, 2026년 3월 현재, 언론정보국(PIB)에 따르면 인도의 국내 의약품 시장 규모는 600억 달러이며, 2030년에는 1,300억 달러로 확대될 것으로 예측됩니다. 또한, 인도에는 60개의 치료 분야에 걸쳐 약 6만 개의 제네릭 브랜드가 존재합니다. 인도의 제약 부문은 생산량 기준 세계 3위, 시장 규모 기준 11위를 차지하고 있으며, 3,000개 이상의 기업과 10,500개의 제조 거점으로 구성되어 있습니다. 이러한 성장을 통해 다양한 치료 요구에 부응하는 처방약 공급, 접근성 및 보급이 촉진되고 있습니다.
질염 치료제 시장 : 지역별 분석
북미는 세균 및 진균 등 감염성 질환의 높은 유병률, 잘 갖춰진 의료 인프라, 그리고 생식 건강에 대한 인식 제고에 힘입어 질염 치료제 시장에서 두드러진 위치를 차지하고 있습니다. 예를 들어, 2025년 5월 기준 미국 질병통제예방센터(CDC)의 추정에 따르면, 미국 내 진균성 질환으로 인한 사망자 수, 입원자 수 및 외래 환자 수는 연간 약 7,300명의 사망, 13만 명의 입원, 1,300만 명의 외래 진료로 추정됩니다. CDC의 추정에 따르면, 미국 내 진균 감염증의 경제적 부담은 연간 약 190억 달러에 달하며, 이는 진균 관련 감염증의 유병률이 높음을 보여줍니다. 이러한 동향은 북미에서 효과적인 질염 치료제 및 첨단 치료법에 대한 수요가 높음을 여실히 드러내고 있습니다.
목차
제1장 질염 치료제 시장 개요
제2장 주요 요약
제3장 질염 치료제 주요 시장 동향
제4장 질염 치료제 산업 분석
제5장 질염 치료제 시장 : 높아지는 지정학적 긴장의 영향
제6장 질염 치료제 시장 구도
제7장 질염 치료제 시장 : 질환별
제8장 질염 치료제 시장 : 제품별
제9장 질염 치료제 시장 : 유통 채널별
제10장 질염 치료제 시장 : 지역별
제11장 주요 벤더 분석 : 질염 치료제 산업
제12장 AnalystView 전방위 전망
AJY 26.09.17Vaginitis Therapeutics market size was valued at US$ 4,051.3 Million in 2025, expanding at a CAGR of 8.1% from 2026 to 2033.
Vaginitis therapeutics involves the administration of medications, including antifungals, antibiotics, and hormones, for the treatment of vaginal infections. Such medications are very effective in alleviating symptoms like itching, discharge, and pain.
The types of the major therapeutic agents for vaginitis include nitroimidazole drugs, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazole drugs are antimicrobial drugs and are employed against parasitic, mycobacterial, and anaerobic Gram-positive and Gram-negative bacteria. The route of administration can be oral, topical, and vaginal for conditions such as bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and many more. The end-users include hospitals, gynecology centers, surgery centers, and clinics.
Vaginitis Therapeutics Market- Market Dynamics
Increasing Prevalence of Sexually Transmitted Diseases (STDs) to Propel Market Demand
The rising number of sexually transmitted diseases (STDs), especially trichomoniasis, is one of the major drivers in the Vaginitis Therapeutics market due to the increasing need to treat such illnesses properly using antimicrobial drugs in order to relieve the symptoms, prevent complications, and handle the infection. For instance, in April 2025, according to a study published in Cureus and available through the National Centre for Biotechnology Information (NCBI), based on the results of more than 50,000 patients, the prevalence of sexually transmitted diseases (STDs) was recorded at 16.2%, and it can be expected that an increase in the prevalence rate of such diseases worldwide will lead to an increase in the demand for vaginitis treatments and remedies. This growing disease burden is expected to increase demand for effective vaginitis therapeutics and treatment options.
Vaginitis Therapeutics Market- Segmentation Analysis:
The Global Vaginitis Therapeutics market is segmented on the basis of Disease, Product, Distribution Channel, and Region.
Antibacterial therapies hold a significant share in the Vaginitis Therapeutics market since bacterial vaginosis, that is one of the common subtypes of vaginitis, always requires the use of antibacterial treatment, along with an increase in the awareness regarding different types of vaginitis and an increase in the incidence rate of recurrence of infection. For instance, in May 2026, according to the UK government, the number of antibiotic-resistant bloodstream infections in England increased by 13.1% from 18,103 cases to 20,484 cases. Also, the selected bacterial bloodstream infections increased from 173,513 cases to 183,990 cases, showing the increasing importance of bacteria and their infections and the growing requirement of effective antibacterials. These trends highlight the growing demand for effective antibacterial therapies to manage bacterial infections.
In terms of product type, prescription therapeutics hold a significant share in the Vaginitis Therapeutics market, as these drugs provide a specialised and medically controlled way of treating severe, chronic, and complex vaginal infections. For instance, in March 2026, according to the Press Information Bureau (PIB), the value of the domestic pharma market in India stood at USD 60,000 million and is expected to increase to USD 130,000 million in 2030, while India has approximately 60,000 generic brands in 60 therapeutic segments. The pharma sector in India ranks third in the world in terms of volume and eleventh in terms of value, and the Indian pharma sector consists of more than 3,000 companies with 10,500 manufacturing units. This growth strengthens the availability, accessibility, and adoption of prescription therapeutics across diverse treatment needs.
Vaginitis Therapeutics Market- Geographical Insights
North America holds a notable place in the Vaginitis Therapeutics market, driven by the prevalence of infections such as bacteria and fungi, developed healthcare infrastructure, and increased awareness of reproductive health. For instance, in May 2025, according to the U.S. Centres for Disease Control and Prevention (CDC), the number of fatalities, hospitalisations, and outpatient visits because of fungal diseases in the United States is estimated to be around 7,300 deaths, 130,000 hospitalisations, and 13 million outpatient visits annually from the fungal diseases in the United States. The CDC estimates that the economic burden of fungal infections in the United States is around $19 billion per annum, signifying the high prevalence of fungi-related infections. These trends underscore North America's demand for effective vaginitis therapeutics and advanced treatment options.
Vaginitis Therapeutics Market- Competitive Landscape:
The Vaginitis Therapeutics market is highly fragmented with intense competition among different global companies like Pfizer Inc., Merck & Co. Inc., Bayer AG, Lupin Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. There is an increasing focus of the firms on improving their market position through innovations, R&D spending, joint ventures, and diversifications. In January 2025, Bayer AG intensified its association with Yuhan Corporation through signing a domestic supply contract for its Canesten products in South Korea, which will help make the Canesten products available for treating vaginal fungal infection and vaginitis. These strategic initiatives are expected to intensify competition and drive innovation across the Vaginitis Therapeutics market.
Recent Developments:
In January 2026, Roche Diagnostics gained the CE mark approval of its Cobas(R) BV/CV Assay, which is a molecular diagnostic test that is intended to help diagnose bacterial vaginosis and Candida vaginitis.
In June 2025, Organon teamed up with Evvy to offer increased availability of XACIATO(R) (clindamycin phosphate) vaginal gel 2%, which has been FDA-approved to treat bacterial vaginosis.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VAGINITIS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis AG
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Limited
- Viatris Inc.
- Abbott Laboratories
- Hologic, Inc.
- Roche Diagnostics
- AstraZeneca plc
- Johnson & Johnson
- Procter & Gamble Company
- Lumavita AG
- Organon & Co.
- Alvogen
- ANI Pharmaceuticals, Inc.
- Bausch Health Companies Inc.
- Others
GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Anti-bacterial
- Hormone
- Anti-fungal
GLOBAL VAGINITIS THERAPEUTICS MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- Prescription
- Over-the-counter (OTC)
GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Hospital Pharmacies
- Others
GLOBAL VAGINITIS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Vaginitis Therapeutics Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Vaginitis Therapeutics Market Snippet by Disease
- 2.1.2. Vaginitis Therapeutics Market Snippet by Product
- 2.1.3. Vaginitis Therapeutics Market Snippet by Distribution Channel
- 2.1.4. Vaginitis Therapeutics Market Snippet by Country
- 2.1.5. Vaginitis Therapeutics Market Snippet by Region
- 2.2. Competitive Insights
3. Vaginitis Therapeutics Key Market Trends
- 3.1. Vaginitis Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Vaginitis Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Vaginitis Therapeutics Market Opportunities
- 3.4. Vaginitis Therapeutics Market Future Trends
4. Vaginitis Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Vaginitis Therapeutics Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Vaginitis Therapeutics Market Landscape
- 6.1. Vaginitis Therapeutics Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Vaginitis Therapeutics Market - By Disease
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
- 7.1.2. Anti-bacterial
- 7.1.3. Hormone
- 7.1.4. Anti-fungal
8. Vaginitis Therapeutics Market - By Product
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
- 8.1.2. Prescription
- 8.1.3. Over-the-counter (OTC)
9. Vaginitis Therapeutics Market - By Distribution Channel
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
- 9.1.2. Retail Pharmacies
- 9.1.3. Hospital Pharmacies
- 9.1.4. Others
10. Vaginitis Therapeutics Market - By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Vaginitis Therapeutics Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Vaginitis Therapeutics Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.8. UK
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.8.3. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.8.4. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.9. France
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.9.3. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.9.4. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.10.3. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.10.4. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
- 10.3.11.1. Overview
- 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.11.3. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.11.4. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
- 10.3.12.1. Overview
- 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.12.4. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Overview
- 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
- 10.3.14.1. Overview
- 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.14.3. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.14.4. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.15.3. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.15.4. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
- 10.3.16.1. Overview
- 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.16.3. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.16.4. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.16.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
- 10.3.17.1. Overview
- 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.17.3. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.17.4. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Vaginitis Therapeutics Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.7. China
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.7.3. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.7.4. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.8. India
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.8.3. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.8.4. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.12.4. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.13.4. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.15.3. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.15.4. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.15.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
- 10.4.16.1. Overview
- 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.16.3. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.16.4. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.16.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
- 10.4.17.1. Overview
- 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.17.3. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.17.4. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.17.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Vaginitis Therapeutics Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Vaginitis Therapeutics Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.8.3. UAE Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.8.4. UAE Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.13.3. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.13.4. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.13.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
- 10.6.14.1. Overview
- 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.14.3. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.14.4. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.14.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
- 10.6.15.1. Overview
- 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.15.3. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.15.4. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.15.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Vaginitis Therapeutics Industry
- 11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
- 11.2. Company Profiles
- 11.2.1. Novartis AG
- 11.2.2. Cipla Limited
- 11.2.3. Dr. Reddy's Laboratories Ltd.
- 11.2.4. Glenmark Pharmaceuticals Ltd.
- 11.2.5. Sun Pharmaceutical Industries Limited
- 11.2.6. Viatris Inc.
- 11.2.7. Abbott Laboratories
- 11.2.8. Hologic, Inc.
- 11.2.9. Roche Diagnostics
- 11.2.10. AstraZeneca plc
- 11.2.11. Johnson & Johnson
- 11.2.12. Procter & Gamble Company
- 11.2.13. Lumavita AG
- 11.2.14. Organon & Co.
- 11.2.15. Alvogen
- 11.2.16. ANI Pharmaceuticals, Inc.
- 11.2.17. Bausch Health Companies Inc.
- 11.2.18. Others
12. 360 Degree AnalystView
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
